(Q34445660)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

review article

1 reference

title

Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

main subject

acute coronary syndrome

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

P Meswani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

S A Spinler

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

language of work or name

English

0 references

publication date

1 August 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

954-987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

Angioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary Syndromes

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Mechanisms of arterial thrombosis: foundation for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

21 January 2018

Unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Redefining medical treatment in the management of unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Unmet therapeutic needs in the management of acute ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Unstable angina: current concepts of pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. The ECLA Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. RESCATE Study Group. Resources Used in Acute Coronary Syndromes and Delays in Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The Prognostic Value of Serum Troponin T in Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Prediction of short- and long-term outcomes by troponin t levels in low-risk patients evaluated for acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Prospective study of the role of cardiac troponin T in patients admitted with unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Comparison of troponin T versus creatine kinase-MB in suspected acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Diagnosis and risk stratification of patients with anginal pain and non-diagnostic electrocardiograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Ability of troponin I to predict cardiac events in patients admitted from the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Infectious causes of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Risk stratification of emergency department patients with acute coronary syndromes using P-selectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Correlation of angiographic morphology and clinical presentation in unstable angina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Clinical predictors easily obtained at presentation predict resource utilization in unstable angina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Validated risk stratification model accurately predicts low risk in patients with unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Defining risk in unstable angina: current trial design does not tell us who should be treated and with what therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Recognition of the importance of embolization in atherosclerotic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Ischemic complications after percutaneous transluminal coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Unstable angina and non Q-wave myocardial infarction. Early risk stratification: role of silent ischemia and coronary morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Adjunctive therapies in the treatment of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Reactivation of unstable angina after the discontinuation of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Selected highlights from the 50th Annual Scientific Session of the American College of Cardiology, Orlando, USA, 18-21 March 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The effect of aspirin on C-reactive protein as a marker of risk in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Low molecular weight heparins in the cardiac catheterization laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Dalteparin in combination with abciximab during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Clinical outcomes of bivalirudin for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Recombinant hirudin in clinical practice: focus on lepirudin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Tirofiban. A review of its use in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cost-effectiveness analysis of abciximab: a Canadian hospital perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Economic issues in glycoprotein IIb/IIIa receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Myocardial injury: the acute phase response and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Statins: effective antiatherosclerotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Optimal treatment of patients with acute coronary syndromes and non-ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Six-Month Outcome in Patients With Myocardial Infarction Initially Admitted to Tertiary and Nontertiary Hospitals fn1fn1This project was funded by Grant 92/0009 from the Fondo de Investigación Sanitaria, Madrid and by Grant CIRIT/SGR 9500167 from th

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Prognostic Value of the Admission Electrocardiogram in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Comparison of the prognostic value of C-Reactive protein and troponin I in patients with unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

Molecular Fingerprint of Interferon-γ Signaling in Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.11.954.34527

10.1592/PHCO.21.11.954.34527

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11718501%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference